David Fabrizio

David Fabrizio has an extensive work experience in the biotechnology and pharmaceutical industry. David began their career at Massachusetts General Hospital, where they worked at Harvard Medical School from 2002 to 2004. David then joined Adnexus, a startup focused on therapeutic protein binders, as a Staff Scientist from 2004 to 2013. After Adnexus was acquired by Bristol-Myers Squibb, they continued working there until 2013. In 2013, they joined AbVitro Inc. as a Senior Scientist, focusing on the discovery of therapeutic targets. AbVitro was later acquired by Juno Therapeutics in 2015. Since 2015, David has been working at Foundation Medicine. David has held various leadership roles, including Vice President of Early Clinical Development, Vice President of Translational Strategy, and Vice President of Product Development. David has also served as the Development Franchise Leader for Solid Tumors & Immuno-oncology and as the Leader of Cancer Immunotherapy.

David Fabrizio earned a Bachelor of Science degree in Molecular Biology and Biological Sciences from the University of Vermont between 1998 and 2002. Additionally, they hold a certification from the American Association of Cancer Research, obtained in 2014.